Shenzhen Hepalink Pharma invested $36.5 million in Kymab Group, a British mAb startup that develops first-in-class candidates. The investment was part of a $100 million Series C round. Founded in 2010, Kymab expects to begin clinical trials of its most advanced candidate next year. Hepalink, which started as a heparin API supplier, has been expanding its product mix through M&A. Also, in 2015, Hepalink paid $206 million to acquire a US biologics contract development/manufacturing company, Cytovance, which Kymab cited as an important addition to its working relationships.
